Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
NCT06299319Phase 1Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in obsessive compulsive disorder (OCD), sponsored by Center for Addiction and Mental Health. Primary endpoints: Feasibility of administering psilocybin, Incidence of adverse events and 1 more. Started Sep 2024; status: completed.
02
Drugs
psilocybin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT06299319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299319.